Sage Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Sage Therapeutics kazanç ve gelirin sırasıyla yıllık 37.9% ve 31.5% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 38.3% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -117.4% olacağı tahmin edilmektedir.

Anahtar bilgiler

37.9%

Kazanç büyüme oranı

38.3%

EPS büyüme oranı

Biotechs kazanç büyümesi	42.1%
Gelir büyüme oranı	31.5%
Gelecekteki özkaynak getirisi	-117.4%
Analist kapsamı	Good
Son güncelleme	18 Dec 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

BST:SG7 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	159	-195	-67	-135	16
12/31/2025	96	-245	-263	-230	18
12/31/2024	42	-400	-356	-272	18
9/30/2024	106	-338	-320	-320	N/A
6/30/2024	97	-446	-374	-374	N/A
3/31/2024	91	-503	-425	-425	N/A
12/31/2023	86	-541	-541	-541	N/A
9/30/2023	11	-656	-549	-548	N/A
6/30/2023	10	-592	-532	-531	N/A
3/31/2023	9	-558	-507	-506	N/A
12/31/2022	8	-533	-461	-460	N/A
9/30/2022	6	-510	-432	-431	N/A
6/30/2022	6	-503	-381	-381	N/A
3/31/2022	6	-484	-377	-377	N/A
12/31/2021	6	-458	-379	-378	N/A
9/30/2021	1,114	642	730	730	N/A
6/30/2021	1,114	666	708	708	N/A
3/31/2021	1,113	637	692	692	N/A
12/31/2020	1,114	606	664	664	N/A
9/30/2020	7	-537	-464	-463	N/A
6/30/2020	9	-612	-504	-501	N/A
3/31/2020	9	-644	-520	-515	N/A
12/31/2019	7	-680	-534	-529	N/A
9/30/2019	5	-670	-520	-514	N/A
6/30/2019	2	-613	-470	-465	N/A
3/31/2019	91	-462	-335	-332	N/A
12/31/2018	90	-373	-264	-261	N/A
9/30/2018	90	-284	-221	-218	N/A
6/30/2018	90	-235	N/A	-184	N/A
3/31/2018	N/A	-288	N/A	-243	N/A
12/31/2017	N/A	-270	N/A	-219	N/A
9/30/2017	N/A	-257	N/A	-194	N/A
6/30/2017	N/A	-221	N/A	-179	N/A
3/31/2017	N/A	-185	N/A	-146	N/A
12/31/2016	N/A	-159	N/A	-119	N/A
9/30/2016	N/A	-132	N/A	-103	N/A
6/30/2016	N/A	-118	N/A	-92	N/A
3/31/2016	N/A	-108	N/A	-84	N/A
12/31/2015	N/A	-94	N/A	-71	N/A
9/30/2015	N/A	-78	N/A	-61	N/A
6/30/2015	N/A	-64	N/A	-49	N/A
3/31/2015	N/A	-47	N/A	-36	N/A
12/31/2014	N/A	-36	N/A	-27	N/A
9/30/2014	N/A	-29	N/A	-23	N/A
6/30/2014	N/A	-24	N/A	-21	N/A
3/31/2014	N/A	-21	N/A	-20	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: SG7 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: SG7 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: SG7 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: SG7 şirketinin gelirinin (yıllık 31.5% ) German pazarından (yıllık 5.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: SG7 şirketinin gelirinin (yıllık 31.5% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: SG7 3 yıl içinde kârsız olması bekleniyor.

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/23 19:01
Gün Sonu Hisse Fiyatı	2024/12/04 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Sage Therapeutics, Inc. 39 Bu analistlerden 18, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Joel Beatty	Baird
Esther Lannie Hong	Berenberg
null null	BMO Capital Markets Equity Research

Sage Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease

Sage Therapeutics, Inc.'s CFO Kimi Iguchi to Depart Amid Leadership Changes

Sage Therapeutics, Inc. Announces Executive Changes

Sage Therapeutics, Inc. to Report Q3, 2024 Results on Oct 29, 2024

Sage Therapeutics Announces Topline Results from the Phase 2 Lightwave Study of Dalzanemdor (Sage-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’S Disease

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Insufficient new directors

Holzer & Holzer, LLC Announces a Class Action Lawsuit Has Been Filed Against Sage Therapeutics, Inc

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$1.70 loss per share (vs US$2.68 loss in 2Q 2023)

Insufficient new directors

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of Sage-324 (BIIB124) for the Treatment of Essential Tremor

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 2500 Growth Index

Sage Therapeutics, Inc. Announces Topline Results from the Phase 2 SURVEYOR Study

Insufficient new directors

Sage Therapeutics, Inc., Annual General Meeting, Jun 10, 2024

First quarter 2024 earnings released: US$1.80 loss per share (vs US$2.46 loss in 1Q 2023)

Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease

Sage Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Insufficient new directors

Insufficient new directors

Sage Therapeutics, Inc. to Report Q4, 2023 Results on Feb 14, 2024

Sage Therapeutics, Inc. Announces Changes to Board of Directors

Insufficient new directors

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Insufficient new directors

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Sage Therapeutics, Inc. Announces U.S. Food and Drug Administration Granted Sage-718 Orphan Drug Designation for the Treatment of Huntington's Disease

Sage Therapeutics, Inc. Announces Reduction of the Workforce by Approximately 40%

Second quarter 2023 earnings released: US$2.68 loss per share (vs US$2.13 loss in 2Q 2022)

Sage Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Biogen Inc. and Sage Therapeutics, Inc. Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Sage Therapeutics, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Sage Therapeutics, Inc. Announces Resignation of Jeffrey M. Jonas as Chief Innovation Officer

Sage Therapeutics Appoints Laura M. Gault as Chief Medical Officer

Sage Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Sage Therapeutics and Biogen Present Further Analyses from Phase 3 Skylark Study of Zuranolone in Postpartum Depression At the European College of Neuropsychopharmacology (Ecnp) Congress

Sage Therapeutics, Inc. Enters into Settlement Agreement

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 1000 Dynamic Index

Sage Therapeutics, Inc. Provides Zuranolone New Drug Application Update

Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints

Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)

Sage Therapeutics, Inc. to Report Q1, 2022 Results on May 03, 2022

Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 Luminary Study of Sage-718 in Patients with Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease

Sage Therapeutics, Inc. Provides Business Update

Sage Therapeutics, Inc and Biogen Inc Announce Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints

Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology Congress

Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD

Third quarter 2021 earnings released: US$2.21 loss per share (vs US$2.03 loss in 3Q 2020)

President recently bought €861k worth of stock

Second quarter 2021 earnings released: US$1.83 loss per share (vs US$2.63 loss in 2Q 2020)

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 3000E Growth Index

Independent Chairman recently bought €825k worth of stock

Sage Therapeutics, Inc. and Biogen Inc. Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder

Investor sentiment improved over the past week

Sage Therapeutics, Inc. to Host Sage Science Spotlight: SAGE-718 In Depth

First quarter 2021 earnings released: US$1.64 loss per share (vs US$2.44 loss in 1Q 2020)

Chief Operating Officer has left the company

Sage Therapeutics, Inc. Announces Continued Positive Zuranolone Data for Both 30 Mg and 50 Mg Doses in Open-Label SHORELINE Study in Patients with MDD

Sage Therapeutics, Inc. Announces Departure of Mike Cloonan as Chief Operating Officer, Effective May 3, 2021

Revenue beats expectations

Full year 2020 earnings released: EPS US$11.66 (vs US$13.38 loss in FY 2019)

Sage Therapeutics, Inc. to Report Q4, 2020 Results on Feb 24, 2021

New 90-day high: €72.48

Sage Therapeutics, Inc. Appoints Barry Greene as President

Sage Therapeutics, Inc. Enters into A Collaboration and License Agreement with Biogen Ma Inc. and Biogen International Gmbh

Third quarter 2020 earnings released: US$2.03 loss per share

Revenue misses expectations

New 90-day high: €66.96

Sage Therapeutics, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day high: €58.04

Sage Therapeutics, Inc. Announces Positive Interim, Topline Zuranolone Safety and Tolerability Data from Open-Label SHORELINE Study in Patients with MDD